---
run_id: halo-evidence-vs-diagnosis-validation-v7-substrate-workflow-01
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: substrate_workflow
run_number: 1
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 103
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
condition_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
output_file: model-outputs/substrate_workflow.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `substrate_workflow`, run 1 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 103, on the frozen condition packet.

## Output

I recommend that you advise the CEO to **run the targeted evidence pass** (Option 2).

### Reasoning
The current "upbeat story" presented for the board packet is a textbook instance of the **Halo Effect** (BK-0048-card-001). The shift in leadership’s perception—moving from describing the team as "too bespoke and reactive" to "customer-obsessed and disciplined"—coincides exactly with a bump in revenue. Per BK-0048, these trait assessments are not independent evidence of improved discipline; they are reflections of the performance signal. Because the revenue bump is largely artificial (driven by discounts and early-renewal incentives), the "halo" is masking a lack of fundamental product-market fit.

Furthermore, the company is currently confusing execution targets with **Validated Learning** (BK-0007-card-001). Revenue retention and "positive quotes" collected by account managers are vanity metrics in this context; they do not prove that the product provides value to the end-user. The empirical evidence—the 31% front-line retention rate and the abandonment in regulated insurance queues—suggests that the product is failing the people who actually use it.

To commit to scaling (Option 1) or pivoting (Option 3) right now would be to execute a plan without a valid **Diagnosis** (BK-0001-card-001). A real strategy requires a diagnosis that isolates the factors that actually matter. Currently, the company does not know if the primary bottleneck is "auditor explainability" (a segment-specific issue) or a more general lack of utility for front-line reviewers (a product-wide issue). Scaling a product with a 31% retention rate is not a strategy; it is an expensive gamble based on contaminated data.

### The Strongest Reason Against This Recommendation
**Opportunity Cost and Momentum Loss.** The board locks the budget in twelve days. Pausing discounts and instrumenting behavior takes time and creates a "lull" in the upbeat narrative. If the CEO believes there is a narrow window to capture the mid-market before a competitor does, "slowing down to learn" may be perceived as a lack of urgency or a failure to capitalize on a perceived win. By choosing the evidence pass, you are sacrificing the immediate (though artificial) appearance of aggressive growth for the sake of long-term viability.

### Observable Evidence That Would Change My Mind
I would change this recommendation to **Option 3 (Narrow the plan to regulated compliance)** if the evidence pass reveals that the 31% front-line retention is consistent across *all* segments, but the "champion" usage (the operations leaders) is exceptionally high and high-value in the regulated insurance sector. If the "champion" behavior is the actual value driver—meaning the product is a management tool rather than a reviewer tool—then the diagnosis changes, and a pivot to a specific, high-value workflow (regulated compliance) becomes the most logical guiding policy.
